Passalacqua Giovanni, Milanese Manlio, Mincarini Marcello, Ciprandi Giorgio, Guerra Laura, Scordamaglia Antonio, Canonica Giorgio W
Allergy and Respiratory Diseases, DIMI, Department of Internal Medicine, Genoa University, Italy.
Int Arch Allergy Immunol. 2002 Nov;129(3):242-7. doi: 10.1159/000066777.
Adverse reactions to drugs are common in the clinical practice. Many outpatients are frequently referred to allergists in order to determine which drugs they can safely take in the future.
We set up an oral single-dose tolerance test procedure to find out for each patient one or more alternative drugs that can be taken when needed.
452 outpatients (130 male, 322 female) with well-documented reactions (urticaria/angioedema, respiratory symptoms, laryngeal edema, anaphylaxis, exfoliative skin diseases) underwent the challenge. All tests were preceded by a single-blind placebo: if a reaction occurred, a second placebo was administered. Otherwise, a single dose (1/10 of the therapeutic one) of an alternative drug was given blindly and the patient was then observed for 6 h. The drugs used were different in structure from those suspected of having caused the adverse reaction. The patients were followed up at 4- to 6-month intervals, in order to detect any reaction that may have occurred with the tested drugs.
98 patients (89 women) had untoward reactions after the first placebo and 34 out of them reacted to the second placebo, too. During challenges the reaction rate ranged between 4.6 and 9.0%; these reactions were easily managed and none of them was severe. We followed up 407 patients: 87.2% of them were able to use one or more of the suggested drugs without reactions, 9.3% did not take the drugs and only 3.5% reported reactions to the previously tested drugs.
The challenge procedure proved to be a simple tool for managing patients with adverse reactions to drugs. Its safety and reliability were validated by a long-term follow-up.
药物不良反应在临床实践中很常见。许多门诊患者经常被转诊至过敏症专科医生处,以确定他们未来可以安全服用哪些药物。
我们建立了一种口服单剂量耐受性测试程序,以找出每位患者在需要时可以服用的一种或多种替代药物。
452例有明确不良反应记录(荨麻疹/血管性水肿、呼吸道症状、喉水肿、过敏反应、剥脱性皮肤病)的门诊患者(130例男性,322例女性)接受了激发试验。所有试验前均先给予单盲安慰剂:如果出现反应,则给予第二剂安慰剂。否则,盲目给予单剂量(治疗剂量的1/10)的替代药物,然后观察患者6小时。所使用的药物在结构上与怀疑引起不良反应的药物不同。对患者进行4至6个月的随访,以检测测试药物可能发生的任何反应。
98例患者(89例女性)在首次服用安慰剂后出现不良反应,其中34例对第二剂安慰剂也有反应。在激发试验期间,反应率在4.6%至9.0%之间;这些反应易于处理,均不严重。我们对407例患者进行了随访:其中87.2%的患者能够使用一种或多种建议的药物而无反应,9.3%的患者未服用这些药物,只有3.5%的患者报告对先前测试的药物有反应。
激发试验被证明是一种管理药物不良反应患者的简单工具。其安全性和可靠性通过长期随访得到了验证。